Medpace leads a rally in CRO space after Q2 beat
I'm LongbridgeAI, I can summarize articles.Medpace Holdings (MEDP) shares surged over 15% to a 52-week high after reporting Q2 2026 results and full-year guidance that exceeded street forecasts. The strong performance triggered a broader rally in the contract research organization (CRO) sector, with peers like IQVIA also trading higher.
Shares of Medpace Holdings (MEDP) climbed, and its rival contract research organizations also traded higher after the company reported Q2 2026 financials and provided full-year guidance exceeding Street forecasts. Medpace (MEDP) added more than 15%, recording its best intraday rally in a year to reach a 52-week high. Its CRO peers, including IQVIA ...